Business Description
Lantern Pharma Inc
NAICS : 325412
SIC : 2834
ISIN : US51654W1018
Share Class Description:
LTRN: Ordinary SharesTotal Employee Number:
16Description
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 107.17 | |||||
Equity-to-Asset | 0.48 | |||||
Debt-to-Equity | 0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -7.4 | |||||
3-Year EPS without NRI Growth Rate | -6.2 | |||||
3-Year FCF Growth Rate | -6.9 | |||||
3-Year Book Growth Rate | -51.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -12.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.09 | |||||
9-Day RSI | 36.23 | |||||
14-Day RSI | 40.02 | |||||
3-1 Month Momentum % | 41.42 | |||||
6-1 Month Momentum % | 11.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.87 | |||||
Quick Ratio | 1.87 | |||||
Cash Ratio | 1.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -162.81 | |||||
ROA % | -113 | |||||
ROIC % | -5253 | |||||
3-Year ROIIC % | 608.06 | |||||
ROC (Joel Greenblatt) % | -11222.97 | |||||
ROCE % | -169.79 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 9.48 | |||||
Price-to-Tangible-Book | 9.61 | |||||
EV-to-EBIT | -1.88 | |||||
EV-to-Forward-EBIT | -1.18 | |||||
EV-to-EBITDA | -1.88 | |||||
EV-to-Forward-EBITDA | -0.06 | |||||
EV-to-FCF | -2.07 | |||||
| Price-to-Net-Current-Asset-Value | 10.28 | |||||
| Price-to-Net-Cash | 12.96 | |||||
Earnings Yield (Greenblatt) % | -53.19 | |||||
FCF Yield % | -40.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LTRN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lantern Pharma Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.45 | ||
| Beta | 4.597 | ||
| 3-Year Sharpe Ratio | 0.31 | ||
| 3-Year Sortino Ratio | 0.61 | ||
| Volatility % | 116.7 | ||
| 14-Day RSI | 40.02 | ||
| 14-Day ATR ($) | 0.324208 | ||
| 20-Day SMA ($) | 3.5215 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 1.11 - 5.7441 | ||
| Shares Outstanding (Mil) | 12.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lantern Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lantern Pharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 09:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 114 days | ||
| General meeting for 2026 | 2026-09-18 11:00 | In 59 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 22 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 3.13 (+22.75%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 16:30 | 1.12 (-49.78%) | ||
| Annual report for 2025 | 2026-03-30 | 1.12 (-49.78%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 1.12 (-49.78%) | ||
| Third quarter earnings conference call for 2025 | 2025-11-13 09:00 | 3.48 (-1.97%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 3.48 (-1.97%) |
Show
Entries
Lantern Pharma Inc Frequently Asked Questions
What is Lantern Pharma Inc(LTRN)'s stock price today?
The current price of LTRN is $2.98. The 52 week high of LTRN is $5.74 and 52 week low is $1.11.
When is next earnings date of Lantern Pharma Inc(LTRN)?
The next earnings date of Lantern Pharma Inc(LTRN) is 2026-08-13 Est..
Does Lantern Pharma Inc(LTRN) pay dividends? If so, how much?
Lantern Pharma Inc(LTRN) does not pay dividend.
Guru Commentaries on NAS:LTRN
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers